Now Available: Acute Myeloid Leukemia (AML) - Pipeline Assessment and Market Forecasts to 2017

New Pharmaceuticals research report from GlobalData is now available from Fast Market Research
Spread the Word
Listed Under



Massachusetts - US

Sept. 15, 2010 - PRLog -- GlobalData has released its pharmaceutical report, "Acute Myeloid Leukemia (AML) - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global AML therapeutics market. The report identifies the key trends shaping and driving the global AML therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global AML therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimated the global AML therapeutics market to be worth $174m in 2009. It is expected to grow to $279m with a Compound Annual Growth Rate (CAGR) of 6.1% by 2017. This growth is primarily attributed to the increase in the prevalence of the disease due to the increasing elderly population and the presence of a strong pipeline with many emerging therapies. Pfizer and Genzyme remain the market leaders within the global AML therapeutics market. There is a high level of unmet need in the current AML therapeutics market in terms of both safety and efficacy.


The report provides information on the key drivers and challenges of the AML market. Its scope includes:  

* Annualized global AML market revenues data from 2001 to 2009, forecast for eight years to 2017.
* Pipeline analysis data provides a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as of DNA synthesis inhibitors, HDAC inhibitors, DNA methyltransferase inhibitors and Aurora kinase inhibitors, CD33 antigen targeters, Farnesyl transferase inhibitors and Topoisomerase II inhibitors.
* Analysis of the current and future competition in the global AML market. The key market players covered are Pfizer, Genzyme, Topo Target A/S, and Vion Pharmaceuticals.
* Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
* Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the AML therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

* Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
* Develop business strategies by understanding the trends shaping and driving the global AML therapeutics market.
* Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global AML market in future.
* Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
* Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
* Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
* What's the next big thing in the global AML market landscape? - Identify, understand and capitalize

For more information or to purchase this report, go to:

Partial Table of Contents:

1 Table of contents 3
1.1 List of Tables 4
1.2 List of Figures 4
2 AML Therapeutics Market: Introduction 5
2.1 Overview 5
2.2 GlobalData Pipeline Report Guidance 6
3 AML Therapeutics Market: Market Characterization 7
3.1 AML Market Size 7
3.2 AML Therapeutics Market Forecast and CAGR 9
3.3 Secondary AML Patient Volume and Market Size 10
3.4 Overview 10
3.5 Patient Volume 10
3.6 sAML Revenue and Market Forecast 11
3.7 Drivers and Barriers for the AML Therapeutics Market 11
3.7.1 Drivers for the AML Therapeutics Market 11
3.7.2 Barriers for the AML Therapeutics Market 12
3.8 Opportunity and Unmet Need 13
3.9 Key Takeaway 14
4 AML Therapeutics Market: Competitive Assessment 15
4.1 Overview 15
4.2 Strategic Competitor Assessment 15
4.3 Profiles of the Major Marketed Products in the AML Therapeutics Market 16
4.3.1 Cytarabine (cytosine arabinoside) 16
4.3.2 Doxorubicin 17
4.3.3 Daunorubicin (daunomycin cerubidine) 18
4.3.4 Idarubicin (4-demethoxydaunorubicin) 19
4.4 Key Takeaway 22
5 AML Therapeutics Market: Pipeline Assessment 23
5.1 Overview 23
5.2 Strategic Pipeline Assessment 23
5.2.1 Technology Trends Analytic Framework 23
5.3 AML Therapeutics - Promising Drugs under Clinical Development 24
5.4 Molecule Profiles for Promising Drugs under Clinical Development 25
5.4.1 AC220 25
5.4.2 Elacytarabine (CP-4055) 25
5.4.3 Onrigin 26
5.4.4 Clolar 27
5.4.5 Belinostat 28
5.5 AML Therapeutics Market - Clinical Pipeline by Mechanism of Action 29
5.6 AML Pipeline - Pipeline by Phase of Clinical Development 30
5.6.1 AML Therapeutics - Phase III Clinical Pipeline 30
5.6.2 AML Therapeutics - Phase II Clinical Pipeline 33
5.6.3 AML Therapeutics - Phase I Clinical Pipeline 42
5.6.4 AML Therapeutics - Preclinical Pipeline 46
5.7 Key Takeaway 46
6 AML Market: Implications for Future Market Competition 47
7 AML Therapeutics Market: Future Players in the AML Therapeutics Market 48
7.1 Introduction 48
7.2 Genzyme 48
7.2.1 Overview 48
7.2.2 Leukemia Disease Portfolio 50
7.3 TopoTarget A/S 50
7.3.1 Overview 50
7.3.2 Leukemia Disease Portfolio 51
7.4 Vion Pharmaceutical Inc. 51
7.4.1 Overview 51
7.4.2 Leukemia Disease Portfolio 52
8 AML Market: Appendix 53
8.1 Definitions 53

Full Table of Contents is available at:

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team.  View more research from GlobalData at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
Email:*** Email Verified
Tags:Aml, Therapeutic, Pipeline, Clinical, Leukemia, Inhibitors, Therapeutics, Globaldata, Genzyme, Patient
Industry:Medical, Research, Biotech
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research PRs
Trending News
Top Daily News
Top Weekly News

Like PRLog?
Click to Share